97 related articles for article (PubMed ID: 26011487)
1. Targeted therapies: Notching up dormant tumour-cell deaths to avoid recurrence.
Hutchinson L
Nat Rev Clin Oncol; 2015 Aug; 12(8):437. PubMed ID: 26011487
[No Abstract] [Full Text] [Related]
2. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.
Abravanel DL; Belka GK; Pan TC; Pant DK; Collins MA; Sterner CJ; Chodosh LA
J Clin Invest; 2015 Jun; 125(6):2484-96. PubMed ID: 25961456
[TBL] [Abstract][Full Text] [Related]
3. Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer.
Rizzo P; Osipo C; Pannuti A; Golde T; Osborne B; Miele L
Adv Enzyme Regul; 2009; 49(1):134-41. PubMed ID: 19344631
[No Abstract] [Full Text] [Related]
4. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors.
Hirose H; Ishii H; Mimori K; Ohta D; Ohkuma M; Tsujii H; Saito T; Sekimoto M; Doki Y; Mori M
Oncol Rep; 2010 Jan; 23(1):35-43. PubMed ID: 19956862
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
[TBL] [Abstract][Full Text] [Related]
7. HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage.
Ju JH; Yang W; Oh S; Nam K; Lee KM; Noh DY; Shin I
Biochem J; 2013 Apr; 451(1):123-34. PubMed ID: 23323858
[TBL] [Abstract][Full Text] [Related]
8. Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.
Kaklamani VG; Cianfrocca M; Ciccone J; Kindy K; Rademaker A; Wiley EL; Gradishar W; O'Regan RM
Biomarkers; 2010 Mar; 15(2):191-3. PubMed ID: 19839717
[No Abstract] [Full Text] [Related]
9. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the perivascular stem-cell niche: can we take tumor recurrence down a NOTCH?
Banu MA; Shin BJ; Boockvar JA
Neurosurgery; 2012 Apr; 70(4):N18-9. PubMed ID: 22426056
[No Abstract] [Full Text] [Related]
11. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling and breast cancer.
Reedijk M
Adv Exp Med Biol; 2012; 727():241-57. PubMed ID: 22399352
[TBL] [Abstract][Full Text] [Related]
13. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer.
Zardawi SJ; O'Toole SA; Sutherland RL; Musgrove EA
Histol Histopathol; 2009 Mar; 24(3):385-98. PubMed ID: 19130408
[TBL] [Abstract][Full Text] [Related]
15. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.
Yamaguchi N; Oyama T; Ito E; Satoh H; Azuma S; Hayashi M; Shimizu K; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Ohwada S; Tatsuta K; Inoue J; Semba K; Watanabe S
Cancer Res; 2008 Mar; 68(6):1881-8. PubMed ID: 18339869
[TBL] [Abstract][Full Text] [Related]
16. "Long-term relapses of breast cancer: a working hypothesis.".
Basso Ricci S
Med Hypotheses; 2005; 64(2):428. PubMed ID: 15607581
[No Abstract] [Full Text] [Related]
17. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
18. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
[No Abstract] [Full Text] [Related]
19. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
20. KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.
Saha SK; Choi HY; Kim BW; Dayem AA; Yang GM; Kim KS; Yin YF; Cho SG
Oncogene; 2017 Jan; 36(3):332-349. PubMed ID: 27345400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
